WDI - World Drug Index

WDI (World Drug Index), http //www.derwent.com/products/ Ir/wdi/... 

Figure 10.7 Predictive ability of CoLiBRI to identify ligands of 130 test binding pockets from the WDI (World Drug Index) and the original 800 ligands.

Probably the most widely adopted and well-known method for estimating the likelihood of a compound (drug) being well absorbed is the rule-of-5 described by Lipinski and co-workers [1]. In analyzing 2245 compounds from the World Drug Index (WDI) database that were either considered for, or entered into, Phase II clinical trials, these authors developed the following rules ... 

WDI, the Derwent World Drug Index, is available from Derwent Publications Ltd., http //thomsonderwent.com/products/ Ir/wdi/ and from Daylight Chemical Information Systems, http //www.daylight.com/ products/databases /W DI. html. 

Most prediction tools for druglikeness use the MDL Available Chemicals Directory (ACD) [89] as a list of nondrugs and one of three databases as a list of drugs MDL Drug Data Report (MDDR) [89], MDL Comprehensive Medicinal Chemistry (CMC) [89], or Derwent World Drug Index (WDI) [90]. 

WDI The World Drug Index is available from Derwent Information, 14 Great Queen St., London W2 5DF, UK. 

Thompson Derwent. Thompson Derwent World Drug Index scientific.thomson.-com/products/wdi. 

The failure of drugs at later stages of development, particularly in clinical trials, is very expensive for drug developers and, more importantly, patients. To better understand the key reasons for these failures, Lipinski et al,14 undertook an analysis of the properties of compounds that entered Phase II human clinical trials. They selected a subset of 2245 compounds from the World Drug Index (WDI) database of over 50000 compounds after eliminating the majority of compounds for various well-reasoned criteria. This subset of compounds had assigned trade names and, as a result, were assumed to have entered Phase II oral efficacy studies and be expected to have superior physico-chemical properties since they would have passed most of the other earlier clinical trial hurdles. 

In 2001, Lee and Schneider17 compared the properties of trade drugs (taken from the Derwent World Drug Index, WDI, n=5151) and natural products (taken from the BioScreenNP database, n= 10 495). These investigators described the comparison of parameters applicable only to the rule of five (molecular weight, log P, number of H donors per molecule, number of N per molecule, number of O per molecule and percentage of rule of five alerts). 

---